2018
DOI: 10.1007/s10549-018-4974-9
|View full text |Cite
|
Sign up to set email alerts
|

Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…In 2018, the combination of palbociclib and fulvestrant has accomplished promising results in the treatment of a patient with BNEN [ 33 ]. In addition, potential targets have been identified to explore potential novel therapeutic approaches for BNEN, such as PIK3CA, trophoblast cell surface antigen-2 (TROP-2), and programmed cell death ligand-1 (PD-L1) [ 23 , [34] , [35] , [36] ]. We look forward to the development of new drugs to bring a new dawn to the treatment of BNEN.…”
Section: Discussionmentioning
confidence: 99%
“…In 2018, the combination of palbociclib and fulvestrant has accomplished promising results in the treatment of a patient with BNEN [ 33 ]. In addition, potential targets have been identified to explore potential novel therapeutic approaches for BNEN, such as PIK3CA, trophoblast cell surface antigen-2 (TROP-2), and programmed cell death ligand-1 (PD-L1) [ 23 , [34] , [35] , [36] ]. We look forward to the development of new drugs to bring a new dawn to the treatment of BNEN.…”
Section: Discussionmentioning
confidence: 99%